Novartis CEO Touts R&D 'Wild Cards' As Proof Of Deep Pipeline
Multi-Billion Dollar Opportunities In Development
Potentially transformative treatments for severe asthma, COPD and osteoarthritis are among some of the below-the-radar projects the Swiss major is advancing, according to Vas Narasimhan.
You may also be interested in...
Successful Phase III data for UCB’s C5 inhibitor zilucoplan adds to a similarly positive Phase III readout for its rozanolixizumab in December, but details are lacking. UCB is the only company with two mechanisms for MG.
Long touted as one of the drugs to watch in the Swiss giant's pipeline, iscalimab's chances of replacing tacrolimus as the standard of care preventing organ rejection in transplant patients have been dealt a hefty blow after a Phase II trial failure.
The company will review a challenging quarter next week when its financials will reveal that certain parts of the business are still feeling the effects of the COVID-19 pandemic, its eye drugs in particular.